The clinical trial showed this experimental medication to be much more effective than any existing GLP-1 drug. But that much weight loss comes with risks.

We never know what demons other people are fighting, even if we think we see their problems from the outside. Those who ...

Retatrutide, originally developed by Eli Lilly, has found a loyal fan base—even though clinical trials of the drug still ...

Retatrutide is an investigational triple agonist developed by Eli Lilly that targets GLP-1, GIP and glucagon receptors, and early trials suggest very strong ...

The global health organization now officially backs drugs like Wegovy for obesity management. But it might be more symbolic ...

Step aside, semaglutide—retatrutide is showing the most impressive weight loss results of any obesity drug to date.

Medication compounding Enhance MD partners with reputable 503A compounding pharmacies, such as Rite-Away Pharmacy, Vios Compounding Pharmacy, and TruMedsRx, to formulate your GLP-1 injections in ...

Popular GLP-1 medications such as Ozempic may carry an unexpected link to a lower risk of epilepsy in people with type 2 ...

A preliminary study of people with diabetes suggests that use of glucose-lowering GLP-1 drugs may be linked to a lower risk of developing epilepsy. The study was published on December 10, 2025, in ...

Semaglutide, a GLP-1 receptor agonist (RA), was associated with a significantly lower risk for adult-onset epilepsy in patients with diabetes than other glucose-lowering drugs (GLDs). Notably, this ...

Using tirzepatide is linked to lower risks of developing primary open-angle glaucoma and elevated eye pressure in patients ...

Women with polycystic ovary syndrome are increasingly turning to blockbuster weight-loss drugs from Eli Lilly and Novo ...